Skip to main content

Molecular Databases and Molecule Complexity - Part 3



So we can run some numbers, to get an idea of the scale of the issue, and then draw things together (in the next post) with a couple of things we are thinking of ourselves to do in ChEMBL.

Stereocenters
For a molecule stored in a database with a single undefined sp3 stereocenter, there are two possible distinct physical molecules (enantiomers), remember some properties are invariant w.r.t. the stereochemistry (e.g. logP) others aren't (e.g. binding energy to a receptor). As further undefined stereocenters are introduced, the number of possibilities increases as a simple combinatoric product. For three stereocenters, there are therefore 2**3 = 8 possibilities. There are a number of programs available to perform this stereo-enumeration - including stereoplex.

Tautomers
Enumeration of possible tautomers is a complex issue, and there has to be introduced the concept of an energy difference (which will reflect how frequent that tautomer occurs) - however the energy difference between two tautomers is crucially dependent on solvation and stabilisation of a particular tautomer by complexation in a binding site, so it is a not trivial task to treat this matter both comprehensively and accurately. There is probably an interesting average scaling of the number of 'reasonable tautomers' as a function of molecular weight for typical drug like molecules in a database such as ChEMBL (we just haven't looked yet). However, it is an area of active research, and there are many tools available to treat these systems - including MN.TAUTOMER.

Ionizable centers
As per tautomers there is the concept of reasonableness that needs to be applied here - in theory, benzene can act as both a base and an acid, but the pKb and pKa will be so outside the range encountered in what we currently understand as life-like conditions that it is irrelevant (the pKa of benzene is ~43). However, for molecules with 'regular' basic and acidic groups, there will be two (or more) states for each ionizable centers. There can be multiple states for some functional groups (e.g. polyprotic acids), such as phosphates which will have multiple pKa values, reflecting increasing levels of overall charge. These charge effects will greatly affect binding to a target. A further complicating factor is that the pKa of molecules is often perturbable by their molecular environment, and this shifting of 'standard' pKa values is often a defining feature of catalytic residues in enzymes.

However, for simple groups such as carboxylic acids, there are two states, and for simple aliphatic amines there are two states to be considered. These combine again in a combinatorial fashion, so a molecule with a simple basic and simple acidic center will have four possible states.

A key feature in dealing with the treatment of the ionization state of a molecule from a normalised chemical database is via prediction of the pKa/pKb of a molecule. There are many tools available to do this - including ACD/PhysChem Suite.

To further complicate things, the calculation of pKa/Pkb depends on the tautomers that the calculation is performed on.

Conformational flexibility
It is tempting to think of storing three-dimensional structures for molecules, since this information can be used in tasks such as docking of a library of rigid molecules to a receptor, or the generation of pharmacophores from a set of molecules that are known to bind to a receptor. However, in general the number of possible conformers is very large, and when combined with the additional complexities above of undefined stereocenters, tautomers, ionizable centers makes this a very challenging task. To give an idea of the complexity, two sp3-sp3 bonds will have three energy minima around that bond; as the number of rotatable bonds is increased, there will be an approximate combinatoric product, so for three independent sp3-sp3 rotatable bonds there will be 3**3 = 27 plausible conformers. Again these will have different energies (and therefore population frequencies), but again these energies are crucially dependent on tautomers, ionization and the solvent/receptor environment. It is complicated.

A very widely used estimate of the conformational flexibility of a molecule, and the implied entropic cost of ordering a flexible molecule on binding to a receptor, is the number of rotatable bonds.

Again there are many tools for the generation of reasonable three-dimensional conformers for a molecule - including CORINA.


Conclusion
So there is therefore a scale of complexity, molecules that are rigid, have no tautomeric forms, are not acids or bases and have completely defined (or no) stereochemistry are unambiguous, and can be safely used from a database like ChEMBL for things like docking. It is also possible to calculate a variety of descriptors for these molecules, and these calculations will be 'robust'. However it is important to appreciate that many property calculation methods require the selection of a single representative structure from the set of possibles.

Other molecules are more complex, and to obtain a physically relevant structure (or set of low energy structures), may require substantial processing/enumeration, the number of possible physical forms can easily extend into hundreds for drug-like molecules; for example, the simple molecule below, has 96 possible forms to consider for something like docking (and this ignores the very large number of conformational states from the 10 rotatable bonds in the structure, which alone are about 3**10 or over 59,000 'states').

An annotated form of the points of interest in this molecule is



In the next post, we will try and bring this together in the context of the ChEMBL database, and how we normalise our chemical structures on registration, and also how we calculate our descriptors, and some of the assumptions we make in this process.

The image above comes from the ever inspiring xkcd.

Comments

Loving this series; it's good reading material for people starting in cheminformatics! And I'm very much looking forward to the next post! Particularly, your description on how to deal with mixture drugs!
Christophe said…
Beware that the stereochemistry of the 2 centers shown as known may not be absolute!

Popular posts from this blog

Improvements in SureChEMBL's chemistry search and adoption of RDKit

    Dear SureChEMBL users, If you frequently rely on our "chemistry search" feature, today brings great news! We’ve recently implemented a major update that makes your search experience faster than ever. What's New? Last week, we upgraded our structure search engine by aligning it with the core code base used in ChEMBL . This update allows SureChEMBL to leverage our FPSim2 Python package , returning results in approximately one second. The similarity search relies on 256-bit RDKit -calculated ECFP4 fingerprints, and a single instance requires approximately 1 GB of RAM to run. SureChEMBL’s FPSim2 file is not currently available for download, but we are considering generating it periodicaly and have created it once for you to try in Google Colab ! For substructure searches, we now also use an RDKit -based solution via SubstructLibrary , which returns results several times faster than our previous implementation. Additionally, structure search results are now sorted by

Improved querying for SureChEMBL

    Dear SureChEMBL users, Earlier this year we ran a survey to identify what you, the users, would like to see next in SureChEMBL. Thank you for offering your feedback! This gave us the opportunity to have some interesting discussions both internally and externally. While we can't publicly reveal precisely our plans for the coming months (everything will be delivered at the right time), we can at least say that improving the compound structure extraction quality is a priority. Unfortunately, the change won't happen overnight as reprocessing 167 millions patents takes a while. However, the good news is that the new generation of optical chemical structure recognition shows good performance, even for patent images! We hope we can share our results with you soon. So in the meantime, what are we doing? You may have noticed a few changes on the SureChEMBL main page. No more "Beta" flag since we consider the system to be stable enough (it does not mean that you will never

ChEMBL brings drug bioactivity data to the Protein Data Bank in Europe

In the quest to develop new drugs, understanding the 3D structure of molecules is crucial. Resources like the Protein Data Bank in Europe (PDBe) and the Cambridge Structural Database (CSD) provide these 3D blueprints for many biological molecules. However, researchers also need to know how these molecules interact with their biological target – their bioactivity. ChEMBL is a treasure trove of bioactivity data for countless drug-like molecules. It tells us how strongly a molecule binds to a target, how it affects a biological process, and even how it might be metabolized. But here's the catch: while ChEMBL provides extensive information on a molecule's activity and cross references to other data sources, it doesn't always tell us if a 3D structure is available for a specific drug-target complex. This can be a roadblock for researchers who need that structural information to design effective drugs. Therefore, connecting ChEMBL data with resources like PDBe and CSD is essen

ChEMBL 34 is out!

We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains:         2,431,025 compounds (of which 2,409,270 have mol files)         3,106,257 compound records (non-unique compounds)         20,772,701 activities         1,644,390 assays         15,598 targets         89,892 documents Data can be downloaded from the ChEMBL FTP site:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/ Please see ChEMBL_34 release notes for full details of all changes in this release:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/chembl_34_release_notes.txt New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding vaccines). 71 out of the 882 newly added EMA drugs are only authorised by EMA, rather than from other regulatory bodies e.g.

A python client for accessing ChEMBL web services

Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d